In wake of FDA rejection, Adventrx discontinues Exelbine until partner emerges
This article was originally published in Scrip
Executive Summary
Adventrx Pharmaceuticals recent meeting with the US FDA about a complete response letter (CRL) the firm received in August on its application for Exelbine (vinorelbine injectable emulsion) as a treatment for non-small-cell lung cancer yielded little good news – an outcome in which investors were none-too pleased.